A ligand-pseudoreceptor system based on de novo designed peptides for the generation of adenoviral vectors with altered tropism

Journal of Gene Medicine

Volumn 10, Issue 4, 2008, Pages 355-367

  Zeng, Yue ^a   Pinard, Maxime ^a,d   Jaime, Jaïro ^a   Bourget, Lucie ^a   Le, Phuong Uyen ^a   O'Connor McCourt, Maureen D ^a   Gilbert, Rénald ^a,b   Massie, Bernard ^a,c,d  

^a NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITÉ LAVAL   (Canada)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Adenovirus; Fiber; Gene therapy; Packaging cells; Pseudoreceptor; Retargeting

Indexed keywords

ADAPTOR PROTEIN; ADENOVIRUS VECTOR; ARGINYLGLYCYLASPARTIC ACID; CD51 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; GREEN FLUORESCENT PROTEIN; LIGAND; PEPTIDE; RECEPTOR; VIRUS RECEPTOR;

ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CELL LINE; CONTROLLED STUDY; GENE TARGETING; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; MOLECULAR INTERACTION; PRIORITY JOURNAL; TRANSGENE; VIROGENESIS;

ADENOVIRIDAE; AMINO ACID MOTIFS; CELL LINE; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HUMANS; LIGANDS; PEPTIDES; RECEPTORS, VIRUS; TRANSDUCTION, GENETIC; VIRUS ASSEMBLY; VIRUS INTERNALIZATION; VIRUS REPLICATION;

ADENOVIRIDAE;

EID: 42049117419     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1155     Document Type: Article

References (55)

1. Mizuguchi H, Hayakawa T. Targeted adenovirus vectors. Hum Gene Ther 2004; 15: 1034-1044.
2. Noureddini SC, Curiel DT. Genetic targeting strategies for adenovirus. Mol Pharm 2005; 2: 341-347.
3. Nicklin SA, Wu E, Nemerow GR, et al. The influence of adenovirus fiber structure and function on vector development for gene therapy. Mol Ther 2005; 12: 384-393.
4. Bergelson JM, Cunningham JA, Droguett G, et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997; 275: 1320-1323.
5. Defer C, Belin MT, Caillet-Boudin ML, et al. Human adenovirus-host cell interactions: comparative study with members of subgroups B and C. J Virol 1990; 64: 3661-3673.
6. Santis G, Legrand V, Hong SS, et al. Molecular determinants of adenovirus serotype 5 fibre binding to its cellular receptor CAR. J Gen Virol 1999; 80: 1519-1527.
7. Wickham TJ, Mathias P, Cheresh DA, et al. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 1993; 73: 309-319.
8. Shayakhmetov DM, Papayannopoulou T, Stamatoyannopoulos G, et al. Efficient gene transfer into human CD34(+) cells by a retargeted adenovirus vector. J Virol 2000; 74: 2567-2583.
9. Denby L, Work LM, Graham D, et al. Adenoviral serotype 5 vectors pseudotyped with fibers from subgroup D show modified tropism in vitro and in vivo. Hum Gene Ther 2004; 15: 1054-1064.
10. Breidenbach M, Rein DT, Wang M, et al. Genetic replacement of the adenovirus shaft fiber reduces liver tropism in ovarian cancer gene therapy. Hum Gene Ther 2004; 15: 509-518.
11. Kanerva A, Mikheeva GV, Krasnykh V, et al. Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clin Cancer Res 2002; 8: 275-280.
12. Ni S, Gaggar A, Di PN, et al. Evaluation of adenovirus vectors containing serotype 35 fibers for tumor targeting. Cancer Gene Ther 2006; 13: 1072-1081.
13. Nakayama M, Both GW, Banizs B, et al. An adenovirus serotype 5 vector with fibers derived from ovine atadenovirus demonstrates CAR-independent tropism and unique biodistribution in mice. Virology 2006; 350: 103-115.
14. Wickham TJ, Tzeng E, Shears LL, et al. Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. J Virol 1997; 71: 8221-8229.
15. Gonzalez R, Vereecque R, Wickham TJ, et al. Transduction of bone marrow cells by the AdZ.F(pK7) modified adenovirus demonstrates preferential gene transfer in myeloma cells. Hum Gene Ther 1999; 10: 2709-2717.
16. Xia H, Anderson B, Mao Q, et al. Recombinant human adenovirus: targeting to the human transferrin receptor improves gene transfer to brain microcapillary endothelium. J Virol 2000; 74: 11359-11366.
17. Belousova N, Korokhov N, Krendelshchikova V, et al. Genetically targeted adenovirus vector directed to CD40-expressing cells. J Virol 2003; 77: 11367-11377.
18. Mailly L, Renaut L, Rogee S, et al. Improved gene delivery to B lymphocytes using a modified adenovirus vector targeting CD21. Mol Ther 2006; 14: 293-304.
19. Wickham TJ, Carrion ME, Kovesdi I. Targeting of adenovirus penton base to new receptors through replacement of its RGD motif with other receptor-specific peptide motifs. Gene Ther 1995; 2: 750-756.
20. Vigne E, Mahfouz I, Dedieu JF, et al. RGD inclusion in the hexon monomer provides adenovirus type 5-based vectors with a fiber knob-independent pathway for infection. J Virol 1999; 73: 5156-5161.
21. Dmitriev IP, Kashentseva EA, Curiel DT. Engineering of adenovirus vectors containing heterologous peptide sequences in the C terminus of capsid protein IX. J Virol 2002; 76: 6893-6899.
22. Vellinga J, de VJ, Myhre S, et al. Efficient incorporation of a functional hyper-stable single-chain antibody fragment protein-IX fusion in the adenovirus capsid. Gene Ther 2007; 14: 664-670.
23. Eto Y, Gao JQ, Sekiguchi F, et al. PEGylated adenovirus vectors containing RGD peptides on the tip of PEG show high transduction efficiency and antibody evasion ability. J Gene Med 2005; 7: 604-612.
24. Dmitriev I, Kashentseva E, Rogers BE, et al. Ectodomain of coxsackievirus and adenovirus receptor genetically fused to epidermal growth factor mediates adenovirus targeting to epidermal growth factor receptor-positive cells. J Virol 2000; 74: 6875-6884.
25. Li E, Brown SL, Von Seggern DJ, et al. Signaling antibodies complexed with adenovirus circumvent CAR and integrin interactions and improve gene delivery. Gene Ther 2000; 7: 1593-1599.
26. Volpers C, Thirion C, Biermann V, et al. Antibody-mediated targeting of an adenovirus vector modified to contain a synthetic immunoglobulin g-binding domain in the capsid. J Virol 2003; 77: 2093-2104.
27. Carette JE, Graat HC, Schagen FH, et al. A conditionally replicating adenovirus with strict selectivity in killing cells expressing epidermal growth factor receptor. Virology 2007; 361: 56-67.
28. Pereboeva L, Komarova S, Roth J, et al. Targeting EGFR with metabolically biotinylated fiber-mosaic adenovirus. Gene Ther 2007; 14: 627-637.
29. Campos SK, Barry MA. Comparison of adenovirus fiber, protein IX, and hexon capsomeres as scaffolds for vector purification and cell targeting. Virology 2006; 349: 453-462.
30. Kurachi S, Koizumi N, Sakurai F, et al. Characterization of capsid-modified adenovirus vectors containing heterologous peptides in the fiber knob, protein IX, or hexon. Gene Ther 2007; 14: 266-274.
31. Kirby I, Davison E, Beavil AJ, et al. Identification of contact residues and definition of the CAR-binding site of adenovirus type 5 fiber protein. J Virol 2000; 74: 2804-2813.
32. Roelvink PW, Mi LG, Einfeld DA, et al. Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae. Science 1999; 286: 1568-1571.
33. De Crescemzo G, Litowski JR, Hodges RS, et al. Real-time monitoring of the interactions of two-stranded de novo designed coiled-coils: effect of chain length on the kinetic and thermodynamic constants of binding. Biochemistry 2003; 42: 1754-1763.
34. Massie B, Mosser DD, Koutroumanis M, et al. New adenovirus vectors for protein production and gene transfer. Cytotechnology 1998; 28: 53-64.
35. Lenferink AE, van Zoelen EJ, van Vugt MJ, et al. Superagonistic activation of ErbB-1 by EGF-related growth factors with enhanced association and dissociation rate constants. J Biol Chem 2000; 275: 26748-26753.
36. Massie B, Couture F, Lamoureux L, et al. Inducible overexpression of a toxic protein by an adenovirus vector with a tetracycline-regulatable expression cassette. J Virol 1998; 72: 2289-2296.
37. Mullick A, Xu Y, Warren R, et al. The cumate gene-switch: a system for regulated expression in mammalian cells. BMC Biotechnol 2006; 6: 43.
38. Durocher Y, Perret S, Kamen A. High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. Nucleic Acids Res 2002;30:E9.
39. Cote J, Bourget I., Garnier A, et al. Study of adenovirus production in serum-free 293SF suspension culture by GFP-expression monitoring. Biotechnol Prog 1997; 13: 709-714.
40. Nicklin SA, Von Seggern DJ, Work LM, et al. Ablating adenovirus type 5 fiber-CAR binding and HI loop insertion of the SIGYPLP peptide generate an endothelial cell-selective adenovirus. Mol Ther 2001; 4: 534-542.
41. Jakubczak JL, Rollence ML, Stewart DA, et al. Adenovirus type 5 viral particles pseudotyped with mutagenized fiber proteins show diminished infectivity of coxsackie B-adenovirus receptor-bearing cells. J Virol 2001; 75: 2972-2981.
42. van Beusechem VW, Mastenbroek DCJ, van den Doel PB, et al. Conditionally replicative adenovirus expressing a targeting adapter molecule exhibits enhanced oncolytic potency on CAR-deficient tumors. Gene Ther 2003; 10: 1982-1991.
43. Krasnykh V, Belousova N, Korokhov N, et al. Genetic targeting of an adenovirus vector via replacement of the fiber protein with the phage T4 fibritin. J Virol 2001; 75: 4176-4183.
44. Koizumi N, Mizuguchi H, Sakurai F, et al. Reduction of natural adenovirus tropism to mouse liver by fiber-shaft exchange in combination with both CAR- and alphav integrin-binding ablation. J Virol 2003; 77: 13062-13072.
45. Von Seggern DJ, Huang S, Fleck SK, et al. Adenovirus vector pseudotyping in fiber-expressing cell lines: improved transduction of Epstein-Barr virus-transformed B cells. J Virol 2000; 74: 354-362.
46. Einfeld DA, Brough DE, Roelvink PW, et al. Construction of a pseudoreceptor that mediates transduction by adenoviruses expressing a ligand in fiber or penton base. J Virol 1999; 73: 9130-9136.
47. Douglas JT, Miller CR, Kim M, et al. A system for the propagation of adenoviral vectors with genetically modified receptor specificities. Nat Biotechnol 1999; 17: 470-475.
48. Henning P, Andersson KM, Frykholm K, et al. Tumor cell targeted gene delivery by adenovirus 5 vectors carrying knobless fibers with antibody-binding domains. Gene Ther 2005; 12: 211-224.
49. Martin K, Brie A, Saulnier P, et al. Simultaneous CAR- and alpha V integrin-binding ablation fails to reduce Ad5 liver tropism. Mol Ther 2003; 8: 485-494.
50. Smith TA, Idamakanti N, Rollence ML, et al. Adenovirus serotype 5 fiber shaft influences in vivo gene transfer in mice. Hum Gene Ther 2003; 14: 777-787.
51. Shayakhmetov DM, Gaggar A, Ni S, et al. Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity. J Virol 2005; 79: 7478-7491.
52. Magnusson MK, Hong SS, Boulanger P, et al. Genetic retargeting of adenovirus: novel strategy employing "deknobbing" of the fiber. J Virol 2001; 75: 7280-7289.
53. Magnusson MK, Hong SS, Henning P, et al. Genetic retargeting of adenovirus vectors: functionality of targeting ligands and their influence on virus viability. J Gene Med 2002; 4: 356-370.
54. Ulasov IV, Tyler MA, Han Y, et al. Novel recombinant adenoviral vector that targets the interleukin-13 receptor alpha2 chain permits effective gene transfer to malignant glioma. Hum Gene Ther 2007; 18: 118-129.
55. Kreppel F, Gackowski J, Schmidt E, et al. Combined genetic and chemical capsid modifications enable flexible and efficient de- and retargeting of adenovirus vectors. Mol Ther 2005; 12: 107-117.